Slingshot members are tracking this event:

On August 10th, FDA to give PDUFA decision on Amgen's (AMGN) BLINCYTO (blinatumomab) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 11, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Acute Lymphoblastic Leukemia, Blincyto® (blinatumomab), Pdufa, Phase 3 Tower Study